Emily Hartwell
Assistant Professor of Psychiatry at the Hospital of the University of Pennsylvania
Associate Member, Institute for Translational Medicine and Therapeutics
Research Psychologist, Crescenz Veterans Affairs Medical Center, University of Pennsylvania
Department: Psychiatry
Graduate Group Affiliations
Contact information
3535 Market St.
Suite 500
Philadelphia, PA 19104
Suite 500
Philadelphia, PA 19104
Links
Homepage of the College on Problems of Drug Dependence, I have been a member since 2010.
Homepage of Research Society on Alcohol. I have been a member since 2018.
Homepage of the College on Problems of Drug Dependence, I have been a member since 2010.
Homepage of Research Society on Alcohol. I have been a member since 2018.
Education:
BA (Political Science)
North Carolina State University, 2008.
MA (Psychology)
University of California, Los Angeles, 2013.
PhD (Clinical Psychology)
University of California, Los Angeles, 2018.
BA (Political Science)
North Carolina State University, 2008.
MA (Psychology)
University of California, Los Angeles, 2013.
PhD (Clinical Psychology)
University of California, Los Angeles, 2018.
Post-Graduate Training
Intern, Clinical psychology, West Los Angeles VA Medical Center, 2017-2018.
VA Advanced Fellowship; Clinical Psychology, Crescenz VA Medical Center, 2018-2021.
Permanent linkIntern, Clinical psychology, West Los Angeles VA Medical Center, 2017-2018.
VA Advanced Fellowship; Clinical Psychology, Crescenz VA Medical Center, 2018-2021.
Selected Publications
Kember, RL*, Hartwell, EE*, Xu, H, Rotenberg, J, Almasy, L, Zhou, H, Gelernter, J, & Kranzler, HR. : Phenome-wide association analysis of substance use disorders in a deeply phenotyped sample. Biological Psychiatry 93(6): 536-545, 2023.Kranzler, HR, and Hartwell, EE: Medications for treating alcohol use disorder: A narrative review. Alcohol: Clinical and Experimental Research 47(7), 2023.
Hartwell EE, Feinn R, Morris PE, Gelernter J, Krystal J, Arias AJ, Hoffman M, Petrakis I, Gueorguieva R, Schacht JP, Oslin D, Anton RF, Kranzler HR.: Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction 115(8): 1426-1437, Aug 2020.
Kranzler, HR, Feinn, R, Xu, H, Ho, BL, Saini, D, Nicastro, O, Jacoby, A, Toikumo, S, Gelernter, J, Hartwell, EE, & Kember, RL: Polygenic risk for substance-related traits predicts substance use onset and progression: Sex and population group differences. Addiction 2023.
Vickers-Smith, R, Justice, AC, Becker, W, Rentsch, CT, Curtis, B, Hartwell, EE, Kember, RL, Tate, J, & Kranzler, HR: Racial and ethnic disparities in alcohol use disorder diagnoses in a nationwide longitudinal cohort study of 700,013 US Veterans. American Journal of Psychiatry 2023.
Kember RL, Vickers-Smith R, Xu H, Toikumo S, Niarchou M, Zhou H, Hartwell EE, Crist RC, Rentsch CT; Million Veteran Program, Davis LK, Justice AC, Sanchez-Roige S, Kampman KM, Gelernter J, Kranzler HR.: Cross-ancestry meta-analysis of opioid use disorder uncovers novel loci with predominant effects in brain regions associated with addiction. Nature Neuroscience 25(10): 1279-1287, Oct 2022.
Kranzler, HR, Hartwell, EE: Treating Alcohol Use Disorder With Hallucinogens-Renewed Interest After a 50-Year Hiatus. JAMA Psychiatry 79(10): 945-946, Oct 2022.
Love T, Shabalin AA, Kember RL, Docherty AR, Zhou H, Koppelmans V, Gelernter J, Baker AK, Hartwell E, Dubroff J, Zubieta JK, Kranzler HR.: Unique and joint associations of polygenic risk for major depression and opioid use disorder with endogenous opioid system function. Neuropsychopharmacology 47: 1784–1790, May 2022.
Hartwell EE, Merikangas AK, Verma SS, Ritchie MD; Regeneron Genetics Center, Kranzler HR, Kember RL.: Genetic liability for substance use associated with medical comorbidities in electronic health records of African- and European-ancestry individuals. Addict Biol 27(2): e13130, Mar 2022.
Hartwell EE, Kranzler HR.: Pharmacogenetics of alcohol use disorder treatments: an update. Expert Opin Drug Metab Toxicol 15(7): 553-564, Jul 2019.